DE69133022T2 - Viral verursachte Zerstörung von Neoplastzellen - Google Patents

Viral verursachte Zerstörung von Neoplastzellen

Info

Publication number
DE69133022T2
DE69133022T2 DE69133022T DE69133022T DE69133022T2 DE 69133022 T2 DE69133022 T2 DE 69133022T2 DE 69133022 T DE69133022 T DE 69133022T DE 69133022 T DE69133022 T DE 69133022T DE 69133022 T2 DE69133022 T2 DE 69133022T2
Authority
DE
Germany
Prior art keywords
neoplastic cells
viral destruction
viral
destruction
utilise
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69133022T
Other languages
English (en)
Other versions
DE69133022D1 (de
Inventor
Robert L Martuza
Donald M Coen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
General Hospital Corp
Original Assignee
Harvard College
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, General Hospital Corp filed Critical Harvard College
Publication of DE69133022D1 publication Critical patent/DE69133022D1/de
Application granted granted Critical
Publication of DE69133022T2 publication Critical patent/DE69133022T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69133022T 1990-09-14 1991-09-16 Viral verursachte Zerstörung von Neoplastzellen Expired - Fee Related DE69133022T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58205790A 1990-09-14 1990-09-14

Publications (2)

Publication Number Publication Date
DE69133022D1 DE69133022D1 (de) 2002-07-04
DE69133022T2 true DE69133022T2 (de) 2003-01-02

Family

ID=24327661

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133022T Expired - Fee Related DE69133022T2 (de) 1990-09-14 1991-09-16 Viral verursachte Zerstörung von Neoplastzellen

Country Status (5)

Country Link
EP (1) EP0514603B1 (de)
JP (1) JP3386479B2 (de)
AT (1) ATE218063T1 (de)
CA (1) CA2051289C (de)
DE (1) DE69133022T2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE178490T1 (de) * 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
CA2190290C (en) * 1994-05-13 2011-07-05 Michael J. Mastrangelo A method of inducing an immune response using vaccinia virus recombinants
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
IL118942A (en) * 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
AU7258996A (en) † 1995-10-06 1997-04-28 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
CA2305269C (en) * 1997-10-09 2012-07-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US6602499B1 (en) 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
EP1390046A4 (de) 1999-04-15 2005-04-20 Wellstat Biologics Corp Behandlung von neoplasmen mit viren
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883662A (en) * 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
GB8712528D0 (en) * 1987-05-28 1987-07-01 Clayton Found Res Gene transfer
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells

Also Published As

Publication number Publication date
JP3386479B2 (ja) 2003-03-17
CA2051289A1 (en) 1992-03-15
ATE218063T1 (de) 2002-06-15
CA2051289C (en) 2002-11-26
EP0514603B1 (de) 2002-05-29
DE69133022D1 (de) 2002-07-04
EP0514603A1 (de) 1992-11-25
JPH06100458A (ja) 1994-04-12

Similar Documents

Publication Publication Date Title
DE69133022T2 (de) Viral verursachte Zerstörung von Neoplastzellen
DK1201639T3 (da) Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser
ES2157109T3 (es) Virus citopaticos para el tratamiento y la profilasis de la neoplasia.
DE69804106D1 (de) Reovirus zur behandlung von neoplasmen
UY25263A1 (es) 6-derivados sustitutivos del ácido micofenólico.-
NO922275L (no) Aryletere, deres fremstilling og fremgangsmaate for behandling
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DK0652957T3 (da) Samlede viruspartikler og deres anvendelse i en vaccine imod rotaviral sygdom
NO953329L (no) Rekombinante viruser og deres anvendelse i genterapien for behandling av öyesykdommer
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
PT888114E (pt) Utilizacao de (+)-alfa-(2,3-dimetoxifenil)-1-¬2-(4-fluorofenil)etil|-4-piperidinometanol no tratamento de doencas depressivas e doencas bipolares
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
DE69524388T2 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
ES507444A0 (es) Procedimiento para inactivar virus de la fiebre aftosa.
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DK0480391T3 (da) Emulgatorfrie emulsionspolymerer, deres fremstilling og deres anvendelse i farmaceutiske præparater med forlænget frigivelse af virksomt stof
DE3578305D1 (de) Unkrautvertilgungszusammensetzungen zum vernichten von monokotylen und dikotylen unkraeutern in mais.
DK185489D0 (da) Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
DE3668778D1 (de) Vorrichtung zur laserchirurgie und insbesondere zur keratotomie der cornea (iii).

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee